Search

Displaying results 1571 - 1580 of 9314 in total
  1. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

  2. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. … Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997].

    Synonyms: Asparaginase (E. coli), E. coli Asparaginase
  3. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder. … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.

  4. Drug

    Enzacamene

    go.drugbank.com/drugs/DB11219
    Approved

    While its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada. … It is used in cosmetic products such as sunscreen to provide skin protection against UV rays.

    Mixtures: Bain De Soleil Protection Lotion SPF 15
  5. Drug

    Chloroxine

    go.drugbank.com/drugs/DB01243
    ApprovedWithdrawn

    Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.

  6. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. … Granulocyte colony-stimulating factors (G-CSFs) were introduced in the 1980's to the clinical setting to stimulate neutrophil proliferation and differentiation, thereby reducing the duration and severity

  7. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  8. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    diet and exercise in the management of 2 diabetes (T2DM). … It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.[L34665]

  9. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    due to non-selective steroidal activities [A275513, A275514]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].

  10. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … [L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that